Mona Ahmed Amin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mona Ahmed Amin has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Dina Sabry
Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Badr University in Cairo, Cairo, Egypt
5 shared publications Mohamed Kassem
Department of Pharmaceutics, Cairo University, Cairo, Egypt
3 shared publications- Amira A. Shahin
Cairo Univ, Fac Med, Rheumatol & Rehabil Dept, Cairo, Egypt
2 shared publications - Halla Mohamed Ragab
Biochemistry Department, Genetic Engineering and Biotechnology Research Division, National Research Center, Dokki, Giza Egypt
2 shared publications Magdy Abdel Hamid
Cardiology, and
2 shared publicationsManal Kamal
Mazen Naga, Mona Amin, Dina Algendy, Ahmed Elbadry, May Fawzi, Ayman Foda, Serag Esmat, Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Cairo University, Cairo 11562, Egypt
2 shared publications
Latest Publications
- Open Access
- 24 December 2025
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 37 (1) , 188
Parameters of bowel ultrasound in the assessment of IBD activity: a correlative study with clinical, endoscopic, and biomarker indices
Background: Bowel ultrasonography (BUS) is becoming a viable, non-invasive, affordable, and radiation-free substitute for endoscopy, which is still the gold standard for evaluating Inflammatory bowel diseases activity. BUS can be used for diagnosis, activity evaluation, complication detection, and therapy monitoring. Aim: Our study aimed to evaluate the value of bowel ultrasound in evaluating IBD activity by analyzing the correlation between ultrasonographic parameters, clinical disease indices, endoscopic scores, and fecal calprotectin levels. Patients and methods: This study included 62 Egyptian patients who were previously diagnosed with IBD. All participants underwent clinical assessment, intestinal ultrasound (IUS), fecal calprotectin (FCP) measurement, as well as endoscopy. Ultrasound parameters assessed included bowel wall thickness (BWT), bowel wall stratification, color Doppler signal (CDS), inflammatory fat, and lymphadenopathy. These parameters were correlated with clinical activity indices (SCCAI for UC and CDAI for CD), endoscopic scores (Mayo Endoscopic Subscore for UC and SES-CD for CD), and fecal calprotectin levels. Ultrasound-based scores HUC for UC and IBUS-SAS for CD were also evaluated. Results: HUC correlated significantly with SCCAI and MES, while IBUS-SAS correlated with CDAI and SES-CD. Bowel wall thickness (BWT) was strongly associated with clinical and endoscopic indices in both UC and CD (all p ≤ 0.001), and color Doppler signal (CDS) showed similar significant correlations. BWT correlated with fecal calprotectin in UC, and CDS correlated with fecal calprotectin in CD. In ROC analysis, BWT demonstrated excellent accuracy for predicting active disease in CD (AUC 0.928; cutoff 3.25 mm; 84.6% sensitivity, 87.5% specificity) and in UC (AUC 0.927; cutoff 3.35 mm; 83.3% sensitivity, 100% specificity). Similarly, HUC yielded a strong diagnostic performance in UC (AUC 0.921; cutoff 5.43; 83.3% sensitivity, 100% specificity). CDS was predictive of disease activity in CD (AUC 0.889; 92.3% sensitivity, 87.5% specificity) but had lower discriminative value in UC (AUC 0.686, p = 0.064). Conclusion: Bowel ultrasound, particularly through BWT and CDS parameters, significantly correlates with established clinical, endoscopic, and biomarker indices, supporting its role for disease activity assessment in IBD.
- 24 December 2025
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 37 (1) , 188
Open AccessParameters of bowel ultrasound in the assessment of IBD activity: a correlative study with clinical, endoscopic, and biomarker indices
Background: Bowel ultrasonography (BUS) is becoming a viable, non-invasive, affordable, and radiation-free substitute for endoscopy, which is still the gold standard for evaluating Inflammatory bowel diseases activity. BUS can be used for diagnosis, activity evaluation, complication detection, and therapy monitoring. Aim: Our study aimed to evaluate the value of bowel ultrasound in evaluating IBD activity by analyzing the correlation between ultrasonographic parameters, clinical disease indices, endoscopic scores, and fecal calprotectin levels. Patients and methods: This study included 62 Egyptian patients who were previously diagnosed with IBD. All participants underwent clinical assessment, intestinal ultrasound (IUS), fecal calprotectin (FCP) measurement, as well as endoscopy. Ultrasound parameters assessed included bowel wall thickness (BWT), bowel wall stratification, color Doppler signal (CDS), inflammatory fat, and lymphadenopathy. These parameters were correlated with clinical activity indices (SCCAI for UC and CDAI for CD), endoscopic scores (Mayo Endoscopic Subscore for UC and SES-CD for CD), and fecal calprotectin levels. Ultrasound-based scores HUC for UC and IBUS-SAS for CD were also evaluated. Results: HUC correlated significantly with SCCAI and MES, while IBUS-SAS correlated with CDAI and SES-CD. Bowel wall thickness (BWT) was strongly associated with clinical and endoscopic indices in both UC and CD (all p ≤ 0.001), and color Doppler signal (CDS) showed similar significant correlations. BWT correlated with fecal calprotectin in UC, and CDS correlated with fecal calprotectin in CD. In ROC analysis, BWT demonstrated excellent accuracy for predicting active disease in CD (AUC 0.928; cutoff 3.25 mm; 84.6% sensitivity, 87.5% specificity) and in UC (AUC 0.927; cutoff 3.35 mm; 83.3% sensitivity, 100% specificity). Similarly, HUC yielded a strong diagnostic performance in UC (AUC 0.921; cutoff 5.43; 83.3% sensitivity, 100% specificity). CDS was predictive of disease activity in CD (AUC 0.889; 92.3% sensitivity, 87.5% specificity) but had lower discriminative value in UC (AUC 0.686, p = 0.064). Conclusion: Bowel ultrasound, particularly through BWT and CDS parameters, significantly correlates with established clinical, endoscopic, and biomarker indices, supporting its role for disease activity assessment in IBD.
- Open Access
- 1 January 2024
- Published by Medknow in International Journal of Noncommunicable Diseases
- Vol. 9 (1) , 42-45
Case of hypertriglyceridemia-induced subacute pancreatitis and hypertriglyceridemia-triggered transverse sinus thrombosis in a recently diagnosed diabetic patient and the efficacy of management of hypertriglyceridemia with continuous insulin infusion
A 28-year-old single female diagnosed with transverse sinus thrombosis; she was also discovered to be diabetic with severe hyperlipidemia. She presented by recurrent episodes of diffuse dull aching abdominal pain referred to the back; she was diagnosed with acute pancreatitis with markedly elevated triglyceride (TG) levels. She started medical treatment for hypertriglyceridemia with no improvement. She started four sessions of plasma exchanges with marked improvement of the general condition, abdominal pain and appetite, and TGs declined.While the patient was on plasma exchange she developed catheter related infection so it is stopped and soon triglycerides raised again with recurrence of the abdominal pain and we started insulin infusion with improvement of her condition
- 1 January 2024
- Published by Medknow in International Journal of Noncommunicable Diseases
- Vol. 9 (1) , 42-45
Open AccessCase of hypertriglyceridemia-induced subacute pancreatitis and hypertriglyceridemia-triggered transverse sinus thrombosis in a recently diagnosed diabetic patient and the efficacy of management of hypertriglyceridemia with continuous insulin infusion
A 28-year-old single female diagnosed with transverse sinus thrombosis; she was also discovered to be diabetic with severe hyperlipidemia. She presented by recurrent episodes of diffuse dull aching abdominal pain referred to the back; she was diagnosed with acute pancreatitis with markedly elevated triglyceride (TG) levels. She started medical treatment for hypertriglyceridemia with no improvement. She started four sessions of plasma exchanges with marked improvement of the general condition, abdominal pain and appetite, and TGs declined.While the patient was on plasma exchange she developed catheter related infection so it is stopped and soon triglycerides raised again with recurrence of the abdominal pain and we started insulin infusion with improvement of her condition
- Open Access
- 21 April 2023
- Published by Juniper Publishers in Advanced Research in Gastroenterology & Hepatology
- Vol. 19 (3) , 1-7
Prevalence of Infective and Non-Infective Hepatitis in a Tertiary Fever Hospital: Alexandria Governorate, Egypt
Journal of clinical gastroenterology is part of the Juniper publishers which is devoted to publish subject-specific articles focused on the needs of individual research communities across all areas of biology and medicine. Specific causes of parenchymal liver diseases consist of abundant varieties which give rise to illnesses that are similar in their clinical and pathological features.
- 21 April 2023
- Published by Juniper Publishers in Advanced Research in Gastroenterology & Hepatology
- Vol. 19 (3) , 1-7
Open AccessPrevalence of Infective and Non-Infective Hepatitis in a Tertiary Fever Hospital: Alexandria Governorate, Egypt
Journal of clinical gastroenterology is part of the Juniper publishers which is devoted to publish subject-specific articles focused on the needs of individual research communities across all areas of biology and medicine. Specific causes of parenchymal liver diseases consist of abundant varieties which give rise to illnesses that are similar in their clinical and pathological features.
- Open Access
- 2 May 2022
- Published by Respub Journals
- Vol. 2 (1) , 15-23
Clinical Significance of Serum CD14 and Its Polymorphism as a Biomarker of Non-Alcoholic Fatty Liver Disease
Background: Liver inflammation is deliberated a risk factor for the ongoing liver damage including non-alcoholic steatohepatitis, cirrhosis, and hepatoma. CD14, an effectual mediator for the monocytes activation, has been postulated as a marker of liver inflammation and fibrosis. This study is constructed to detect the alterations in the CD14 serum levels in 40 NAFLD cases and 14 healthy controls along with to analyze the role of CD14 polymorphisms in the causation and severity of Non-Alcoholic Fatty Liver Disease (NAFLD). Liver enzymes, glycated hemoglobin, together with lipid profile were estimated in all included subjects. The diagnosis of NAFLD depends largely on ultrasonography. NAFLD fibrosis score and FIB-4 score were calculated. Serum CD14 was quantified by EnzymeLinked Immunosorbent Assay (ELISA) and C14-159C/T SNP was genotyped via Polymerase Chain Reaction (PCR) and Restriction Fragment Length Polymorphisms (RFLP). Results: Serum CD14 was markedly higher in the diabetic subjects either lean or overweight/obese than the controls (P0.676 (P=1.000). Conclusion: The former observations advocate the potential role of CD14 in both the pathogenesis and progression of NAFLD. Yet, it didn't correlate with the NFS, consequently it couldn't forecast the severity of the disease. Furthermore, no association was distinguished linking CD14 C-(159) T polymorphism and the risk of NAFLD occurrence.
- 2 May 2022
- Published by Respub Journals
- Vol. 2 (1) , 15-23
Open AccessClinical Significance of Serum CD14 and Its Polymorphism as a Biomarker of Non-Alcoholic Fatty Liver Disease
Background: Liver inflammation is deliberated a risk factor for the ongoing liver damage including non-alcoholic steatohepatitis, cirrhosis, and hepatoma. CD14, an effectual mediator for the monocytes activation, has been postulated as a marker of liver inflammation and fibrosis. This study is constructed to detect the alterations in the CD14 serum levels in 40 NAFLD cases and 14 healthy controls along with to analyze the role of CD14 polymorphisms in the causation and severity of Non-Alcoholic Fatty Liver Disease (NAFLD). Liver enzymes, glycated hemoglobin, together with lipid profile were estimated in all included subjects. The diagnosis of NAFLD depends largely on ultrasonography. NAFLD fibrosis score and FIB-4 score were calculated. Serum CD14 was quantified by EnzymeLinked Immunosorbent Assay (ELISA) and C14-159C/T SNP was genotyped via Polymerase Chain Reaction (PCR) and Restriction Fragment Length Polymorphisms (RFLP). Results: Serum CD14 was markedly higher in the diabetic subjects either lean or overweight/obese than the controls (P0.676 (P=1.000). Conclusion: The former observations advocate the potential role of CD14 in both the pathogenesis and progression of NAFLD. Yet, it didn't correlate with the NFS, consequently it couldn't forecast the severity of the disease. Furthermore, no association was distinguished linking CD14 C-(159) T polymorphism and the risk of NAFLD occurrence.
- Open Access
- 9 November 2020
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 65 (AHEAD) , 93-97
Hypoadiponectinemia as a marker of increased cardiovascular risk in patients with non-alcoholic fatty liver disease: correlation with albumin/creatinine ratio
Objective: We assessed plasma adiponectin and its correlation with carotid intima-media-thickness (CIMT), as a marker of atherosclerosis, and urine albumin/creatinine ratio (ACR) in patients with non-alcoholic fatty liver disease (NAFLD). Subjects and methods: The study included 100 Egyptian subjects (50 patients with NAFLD with no history of diabetes or hypertension and 50 age and sex-matched normal healthy control subjects). Urine albumin/creatinine ratio (ACR) was assessed in all participants and fasting plasma adiponectin was measured using ELISA technique. Ultrasonography was used to diagnose NAFLD. CIMT was assessed using high-resolution Doppler ultrasonography. Results: Mild albuminuria was detected in patients with NAFLD (mean urine ACR = 42 +/- 30 mg/g). Plasma adiponectin was significantly lower and urine ACR and CIMT significantly higher in patients with NAFLD as compared with the control group (P < 0.001 for all). A significant negative correlation was found between plasma adiponectin and both urine ACR and CIMT in patients with NAFLD (P <0.001 and <0.05 respectively). A significant positive correlation was also found between CIMT and urine ACR in those patients (P < 0.05). Plasma adiponectin and urine ACR were independent determinants of CIMT in patients with NAFLD (P <0.01 and <0.05 respectively). Conclusion: Patients with NAFLD, without diabetes, have an increased risk of atherosclerosis and cardiovascular disease. Hypoadiponectinemia and low-grade albuminuria are important markers of that risk.
- 9 November 2020
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 65 (AHEAD) , 93-97
Open AccessHypoadiponectinemia as a marker of increased cardiovascular risk in patients with non-alcoholic fatty liver disease: correlation with albumin/creatinine ratio
Objective: We assessed plasma adiponectin and its correlation with carotid intima-media-thickness (CIMT), as a marker of atherosclerosis, and urine albumin/creatinine ratio (ACR) in patients with non-alcoholic fatty liver disease (NAFLD). Subjects and methods: The study included 100 Egyptian subjects (50 patients with NAFLD with no history of diabetes or hypertension and 50 age and sex-matched normal healthy control subjects). Urine albumin/creatinine ratio (ACR) was assessed in all participants and fasting plasma adiponectin was measured using ELISA technique. Ultrasonography was used to diagnose NAFLD. CIMT was assessed using high-resolution Doppler ultrasonography. Results: Mild albuminuria was detected in patients with NAFLD (mean urine ACR = 42 +/- 30 mg/g). Plasma adiponectin was significantly lower and urine ACR and CIMT significantly higher in patients with NAFLD as compared with the control group (P < 0.001 for all). A significant negative correlation was found between plasma adiponectin and both urine ACR and CIMT in patients with NAFLD (P <0.001 and <0.05 respectively). A significant positive correlation was also found between CIMT and urine ACR in those patients (P < 0.05). Plasma adiponectin and urine ACR were independent determinants of CIMT in patients with NAFLD (P <0.01 and <0.05 respectively). Conclusion: Patients with NAFLD, without diabetes, have an increased risk of atherosclerosis and cardiovascular disease. Hypoadiponectinemia and low-grade albuminuria are important markers of that risk.
- 16 June 2020
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 33 (3) , 309-311
COVID-19 and the liver: overview
On 12 March 2020, the WHO declared that the coronavirus disease 2019 (COVID-19) constitutes a pandemic. Cases of liver damage or dysfunction (mainly characterized by moderately elevated serum aspartate aminotransferase levels) have been reported among patients with COVID-19. However, it is currently uncertain whether the COVID-19 related liver damage/dysfunction is due mainly to the viral infection by itself or other coexisting conditions, such as the use of potentially hepatotoxic medications and the coexistence of systemic inflammatory response, respiratory distress syndrome-induced hypoxia, and multiple organ dysfunction. Individuals at high risk for severe COVID-19 are typical of older age and/or present with comorbid conditions such as diabetes, cardiovascular disease, and hypertension. This is also the same profile for those at increased risk for unrecognized underlying liver disease, especially nonalcoholic fatty liver disease. This could make them more susceptible to liver injury from the virus, medications used in supportive management, or hypoxia. So the aim of this review was to illustrate the clinical implications of COVID-19 on the liver in healthy and diseased states as well as the implications of common liver disorders on the outcome of COVID-19.
- 16 June 2020
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 33 (3) , 309-311
COVID-19 and the liver: overview
On 12 March 2020, the WHO declared that the coronavirus disease 2019 (COVID-19) constitutes a pandemic. Cases of liver damage or dysfunction (mainly characterized by moderately elevated serum aspartate aminotransferase levels) have been reported among patients with COVID-19. However, it is currently uncertain whether the COVID-19 related liver damage/dysfunction is due mainly to the viral infection by itself or other coexisting conditions, such as the use of potentially hepatotoxic medications and the coexistence of systemic inflammatory response, respiratory distress syndrome-induced hypoxia, and multiple organ dysfunction. Individuals at high risk for severe COVID-19 are typical of older age and/or present with comorbid conditions such as diabetes, cardiovascular disease, and hypertension. This is also the same profile for those at increased risk for unrecognized underlying liver disease, especially nonalcoholic fatty liver disease. This could make them more susceptible to liver injury from the virus, medications used in supportive management, or hypoxia. So the aim of this review was to illustrate the clinical implications of COVID-19 on the liver in healthy and diseased states as well as the implications of common liver disorders on the outcome of COVID-19.
- 1 June 2020
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 15 (4) , 549-552
Cardio-metabolic problem in Egypt
Thirty years ago, chronic conditions such as diabetes, heart disease, and obesity accounted for less than 45% of the global disease burden. Today, they are the leading causes of death and disability worldwide, having surpassed infectious diseases such as HIV/AIDS and malaria. We have understood for decades the roles of 'classical' risk factors including elevated LDL-cholesterol, hypertension, elevated blood glucose, and smoking in the pathogenesis of cardiovascular disease. More recent research is continuing to define the contribution of other emerging factors to the risk of developing cardiovascular disease, particularly abdominal obesity that is associated with atherogenic dyslipidemia, insulin resistance, chronic inflammation, and prothrombotic state. All these factors constitute the global cardiometabolic risk that plays a significant role in development of cardiovascular disease.
- 1 June 2020
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 15 (4) , 549-552
Cardio-metabolic problem in Egypt
Thirty years ago, chronic conditions such as diabetes, heart disease, and obesity accounted for less than 45% of the global disease burden. Today, they are the leading causes of death and disability worldwide, having surpassed infectious diseases such as HIV/AIDS and malaria. We have understood for decades the roles of 'classical' risk factors including elevated LDL-cholesterol, hypertension, elevated blood glucose, and smoking in the pathogenesis of cardiovascular disease. More recent research is continuing to define the contribution of other emerging factors to the risk of developing cardiovascular disease, particularly abdominal obesity that is associated with atherogenic dyslipidemia, insulin resistance, chronic inflammation, and prothrombotic state. All these factors constitute the global cardiometabolic risk that plays a significant role in development of cardiovascular disease.
- 1 December 2017
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 185 (2) , 484-493
IL-21 as a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection
Hepatitis C virus (HCV) infection is a significant public health problem. The crucial role of interleukin (IL)-21 in HCV has been established. Thus, we aimed to investigate the association of serum IL-21 levels with the virological response to interferon (IFN)-based therapy in a group of Egyptian patients with chronic hepatitis C (CHC). Clinical data were collected from 58 HCV-positive Egyptian patients treated with IFN/ribavirin therapy and 10 non-HCV-infected healthy subjects. Liver and renal function tests, complete blood count, viral markers, and pretreatment IL-21 levels were determined in all patients and healthy controls. Patients who achieved sustained virologic response (SVR) had higher pretreatment median serum IL-21 levels than those who did not. Thus, this study concluded that higher pretreatment serum IL-21 may be useful in predicting SVR in CHC patients.
- 1 December 2017
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 185 (2) , 484-493
IL-21 as a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection
Hepatitis C virus (HCV) infection is a significant public health problem. The crucial role of interleukin (IL)-21 in HCV has been established. Thus, we aimed to investigate the association of serum IL-21 levels with the virological response to interferon (IFN)-based therapy in a group of Egyptian patients with chronic hepatitis C (CHC). Clinical data were collected from 58 HCV-positive Egyptian patients treated with IFN/ribavirin therapy and 10 non-HCV-infected healthy subjects. Liver and renal function tests, complete blood count, viral markers, and pretreatment IL-21 levels were determined in all patients and healthy controls. Patients who achieved sustained virologic response (SVR) had higher pretreatment median serum IL-21 levels than those who did not. Thus, this study concluded that higher pretreatment serum IL-21 may be useful in predicting SVR in CHC patients.
- Open Access
- 15 September 2017
- Published by MDPI AG in Gastroenterology Insights
- Vol. 8 (1) , 1-5
Assessment of Serum Level Cholinesterase as a Biomarker of Liver Cirrhosis in Egyptian Cirrhotic Patients
Serum cholinesterase levels are closely correlated with the severity of liver disease. The aim of the paper was to assess the value of serum cholinesterase in evaluating liver reserve function in cirrhotic patients. 90 patients with liver cirrhosis and thirty healthy control group were included. Liver cirrhosis patients were classified according to child score into three equal groups: Child A liver cirrhosis, Child B liver cirrhosis and Child C liver cirrhosis. Patients were subjected to clinical evaluation, laboratory analysis, abdominal U/S. Measuring serum cholinesterase, and Calculation of both Child and model of end stage liver disease (MELD) scores. The level of serum cholinesterase was higher in control group than the three groups of liver cirrhosis with median (IQR) 17,410 (12,111-21,774), 7528 (5200-9856), 6021 (4500-7542), 3828.5 (1541-6060), respectively P<0.001). And the level of serum cholinesterase was higher in Child A more than Child B and Child C and the level of serum cholinesterase was higher in Child B more than Child C with very strong negative correlation between serum Cholinesterase level and Child score (r=-0.9, P<0.001). Also strong negative correlation between serum Cholinesterase level and MELD score (r=- 0.85, P=0.001), and positive correlation with prothrombin concentration (r=0.554, P=0.009), and serum albumin levels (r=0.582, P=0.0002). Serum cholinesterase is a good biomarker of cirrhosis. Since it distinguishes decompensated from compensated cirrhosis well, low levels in cirrhosis may serve as a useful prognostic marker of advanced liver disease.
- 15 September 2017
- Published by MDPI AG in Gastroenterology Insights
- Vol. 8 (1) , 1-5
Open AccessAssessment of Serum Level Cholinesterase as a Biomarker of Liver Cirrhosis in Egyptian Cirrhotic Patients
Serum cholinesterase levels are closely correlated with the severity of liver disease. The aim of the paper was to assess the value of serum cholinesterase in evaluating liver reserve function in cirrhotic patients. 90 patients with liver cirrhosis and thirty healthy control group were included. Liver cirrhosis patients were classified according to child score into three equal groups: Child A liver cirrhosis, Child B liver cirrhosis and Child C liver cirrhosis. Patients were subjected to clinical evaluation, laboratory analysis, abdominal U/S. Measuring serum cholinesterase, and Calculation of both Child and model of end stage liver disease (MELD) scores. The level of serum cholinesterase was higher in control group than the three groups of liver cirrhosis with median (IQR) 17,410 (12,111-21,774), 7528 (5200-9856), 6021 (4500-7542), 3828.5 (1541-6060), respectively P<0.001). And the level of serum cholinesterase was higher in Child A more than Child B and Child C and the level of serum cholinesterase was higher in Child B more than Child C with very strong negative correlation between serum Cholinesterase level and Child score (r=-0.9, P<0.001). Also strong negative correlation between serum Cholinesterase level and MELD score (r=- 0.85, P=0.001), and positive correlation with prothrombin concentration (r=0.554, P=0.009), and serum albumin levels (r=0.582, P=0.0002). Serum cholinesterase is a good biomarker of cirrhosis. Since it distinguishes decompensated from compensated cirrhosis well, low levels in cirrhosis may serve as a useful prognostic marker of advanced liver disease.
- 23 November 2015
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 36 (2) , 147-155
Comparative Clinical Pharmacokinetics of Midodrine and Its Active Metabolite Desglymidodrine in Cirrhotic Patients with Tense Ascites Versus Healthy Volunteers
Midodrine is an α-agonist prodrug of desglymidodrine used for the management of hypotension, and can also be used for hepatorenal syndrome and cirrhotic patients with tense ascites. The objective of the present work was to study the clinical pharmacokinetic parameters of midodrine and its active metabolite desglymidodrine in cirrhotic patients with tense ascites, which may help in dose selection and improve treatment outcome. This was a prospective, open-label, single-dose, parallel-group study. At first, a pilot study was performed on one healthy volunteer by taking serial blood samples at scheduled time intervals to validate the method of analysis and sampling times. The full study was then conducted by selecting 12 cirrhotic patients with tense ascites in one group and taking nine blood samples. We also selected five healthy volunteers as the control group and took 11 blood samples. Statistically significant differences were observed between the healthy volunteer group and the patients group in the area under the concentration versus time curve (AUC0–t ) and maximum plasma concentration (C max) values of midodrine and desglymidodrine. Based on the results of the pharmacokinetic analysis, the patient group was further subdivided into those receiving the interacting drug ranitidine (five patients) and those not receiving the interacting drug (seven patients). Pharmacokinetic parameters of midodrine can differ significantly in cirrhotic patients with tense ascites from those in healthy individuals. Drug monitoring, dose adjustments, and drug–drug interactions should all be considered during therapy in this vulnerable patient group.
- 23 November 2015
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 36 (2) , 147-155
Comparative Clinical Pharmacokinetics of Midodrine and Its Active Metabolite Desglymidodrine in Cirrhotic Patients with Tense Ascites Versus Healthy Volunteers
Midodrine is an α-agonist prodrug of desglymidodrine used for the management of hypotension, and can also be used for hepatorenal syndrome and cirrhotic patients with tense ascites. The objective of the present work was to study the clinical pharmacokinetic parameters of midodrine and its active metabolite desglymidodrine in cirrhotic patients with tense ascites, which may help in dose selection and improve treatment outcome. This was a prospective, open-label, single-dose, parallel-group study. At first, a pilot study was performed on one healthy volunteer by taking serial blood samples at scheduled time intervals to validate the method of analysis and sampling times. The full study was then conducted by selecting 12 cirrhotic patients with tense ascites in one group and taking nine blood samples. We also selected five healthy volunteers as the control group and took 11 blood samples. Statistically significant differences were observed between the healthy volunteer group and the patients group in the area under the concentration versus time curve (AUC0–t ) and maximum plasma concentration (C max) values of midodrine and desglymidodrine. Based on the results of the pharmacokinetic analysis, the patient group was further subdivided into those receiving the interacting drug ranitidine (five patients) and those not receiving the interacting drug (seven patients). Pharmacokinetic parameters of midodrine can differ significantly in cirrhotic patients with tense ascites from those in healthy individuals. Drug monitoring, dose adjustments, and drug–drug interactions should all be considered during therapy in this vulnerable patient group.